In pancreatic cancer, alterations of TGF-β signaling occur through the mutation of the genes involved in the pathway (including SMAD4); this activity is present in 47% of pancreatic cancer patients (23). This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.